

Referenties

- [1] Bekkering, G.E., Bala, M.M., Reid, K., Kellen, E., Harker, J., Riemsma, R., et al. (2011). Epidemiology of chronic pain and its treatment in The Netherlands. *The Netherlands journal of medicine*. 69(3):141-53.
- [2] Treede, R.D., Rief, W., Barke, A., Aziz, Q., Bennett, M.I., Benoliel, R., et al. (2015). A classification of chronic pain for ICD-11. *Pain*. 156(6):1003-7.
- [3] Nury, E., Schmucker, C., Nagavci, B., Motschall, E., Nitschke, K., Schulte, E., et al. (2022). Efficacy and safety of strong opioids for chronic noncancer pain and chronic low back pain: a systematic review and meta-analyses. *Pain*. 163(4):610-36.
- [4] Baldini, A., Von Korff, M., & Lin, E.H. (2012). A Review of Potential Adverse Effects of Long-Term Opioid Therapy: A Practitioner's Guide. *Prim Care Companion CNS Disord*. 14(3).
- [5] Dowell, D., Haegerich, T.M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain: Morbidity and Mortality Weekly Report [Available from: <https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm>].
- [6] Adewumi, A.D., Hollingworth, S.A., Maravilla, J.C., Connor, J.P., & Alati, R. (2018). Prescribed Dose of Opioids and Overdose: A Systematic Review and Meta-Analysis of Unintentional Prescription Opioid Overdose. *CNS drugs*. 32(2):101-16.
- [7] Higgins, C., Smith, B.H., & Matthews, K. (2019). Evidence of opioid-induced hyperalgesia in clinical populations after chronic opioid exposure: a systematic review and meta-analysis. *Br J Anaesth*. 122(6):e114-e26.
- [8] Association, A.P. (2013). *Diagnostic and Statistical Manual of Mental Disorders 5th Edition*. Washington DC: American Psychiatric Publishing.
- [9] Vowles, K.E., McEntee, M.L., Julnes, P.S., Frohe, T., Ney, J.P., & van der Goes, DN. (2015). Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. *Pain*. 156(4):569-76.
- [10] Manhapra, A. (2022). Complex Persistent Opioid Dependence-an Opioid-induced Chronic Pain Syndrome. *Current treatment options in oncology*. 23(7):921-35.
- [11] Dijkstra, B., van Oor, M., Schellekens, A., de Haan, H., & de Jong, C. (2017). Richtlijn Detoxificatie van psychoactieve middelen; Verantwoord ambulant of intramuraal detoxificeren: Perspectief Uitgevers [Available from: <https://www.resultatenscoren.nl/>].
- [12] Manhapra, A., Arias, A.J., & Ballantyne, J.C. (2018). The conundrum of opioid tapering in long-term opioid therapy for chronic pain: A commentary. *Substance abuse*. 39(2):152-61.
- [13] Mattick, R.P., Breen, C., Kimber, J., & Davoli, M. (2014). Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *The Cochrane database of systematic reviews*. 2014(2):Cd002207.
- [14] CADTH Rapid Response Reports (2016). Buprenorphine/Naloxone Versus Methadone for the Treatment of Opioid Dependence: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health.
- [15] Voon, P., Karamouzian, M., & Kerr, T. (2017). Chronic pain and opioid misuse: a review of reviews. *Subst Abuse Treat Prev Policy*. 12(1):36.
- [16] Neumann, A.M., Blondell, R.D., Hoopsick, R.A., & Homish, G.G. (2019). Randomized clinical trial comparing buprenorphine/naloxone and methadone for the treatment of patients with failed back surgery syndrome and opioid addiction. *J Addict Dis*. 1-9.

- [17] Daitch, J., Frey, M.E., Silver, D., Mitnick, C., Daitch, D., Pergolizzi, J., Jr. (2012). Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. *Pain Physician*. 15(3 Suppl):Es59-66.
- [18] Daitch, D., Daitch, J., Novinson, D., Frey, M., Mitnick, C., Pergolizzi, J., Jr. (2014). Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. *Pain medicine*. 15(12):2087-94.
- [19] Pade, P.A., Cardon, K.E., Hoffman, R.M., & Geppert, C.M. (2012). Prescription opioid abuse, chronic pain, and primary care: a Co-occurring Disorders Clinic in the chronic disease model. *Journal of substance abuse treatment*. 43(4):446-50.
- [20] Rosenblum, A., Cruciani, R.A., Strain, E.C., Cleland, C.M., Joseph, H., Magura, S., et al. (2012). Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol. *J Opioid Manag*. 8(6):369-82.
- [21] Roux, P., Sullivan, M.A., Cohen, J., Fugon, L., Jones, J.D., Vosburg, S.K., et al. (2013). Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. *Pain*. 154(8):1442-8.
- [22] Lutz, P.E., & Kieffer, B.L. (2013). Opioid receptors: distinct roles in mood disorders. *Trends Neurosci*. 36(3):195-206.
- [23] Bruchas, M.R., Land, B.B., & Chavkin, C. (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. *Brain Res*. 1314:44-55.
- [24] Ahmadi, J., & Sefidfard Jahromi, M. (2018). Ultrarapid Influence of Buprenorphine on Major Depression in Opioid-Dependent Patients: A Double Blind, Randomized Clinical Trial. *Subst Use Misuse*. 53(2):286-9.
- [25] Serafini, G., Adavastro, G., Canepa, G., De Berardis, D., Valchera, A., Pompili, M., et al. (2018). The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review. *Int J Mol Sci*. 19(8).
- [26] Schellekens, A.F.A., Veldman, S.E., Suranto, E.S.D., van Rijswijk, S.M., van der Wal, S.E.I., Schene, A.H., et al. (2021). Beneficial Effects of Opioid Rotation to Buprenorphine/Naloxone on Opioid Misuse, Craving, Mental Health, and Pain Control in Chronic Non-Cancer Pain Patients with Opioid Use Disorder. *J Clin Med*. 10(16).
- [27] Veldman, S., van Beek, M., van Rijswijk, S., Ellerbroek, H., Timmerman, H., van der Wal, S., et al. (2021). Effects of opioid rotation to buprenorphine/naloxone on pain, pain thresholds, pain tolerance, and quality of life in patients with chronic pain and opioid use disorder. *Pain*.
- [28] Specialisten FM (2013). *Opiaatverslaving*.
- [29] Meuldijk, D., Giltay, E.J., Carlier, I.V., van Vliet, I.M., van Hemert, A.M., & Zitman, F.G. (2017). A Validation Study of the Web Screening Questionnaire (WSQ) Compared With the Mini-International Neuropsychiatric Interview-Plus (MINI-Plus). *JMIR mental health*. 4(3):e35.
- [30] Butler, S.F., Budman, S.H., Fanciullo, G.J., & Jamison, R.N. (2010). Cross validation of the current opioid misuse measure to monitor chronic pain patients on opioid therapy. *The Clinical journal of pain*. 26(9):770-6.
- [31] Kleykamp, B.A., De Santis, M., Dworkin, R.H., Huhn, A.S., Kampman, K.M., Montoya, I.D., et al. (2019). Craving and opioid use disorder: A scoping review. *Drug and alcohol dependence*. 205:107639.
- [32] Thong, I.S.K., Jensen, M.P., Miró, J., & Tan, G. (2018). The validity of pain intensity measures: what do the NRS, VAS, VRS, and FPS-R measure? *Scandinavian journal of pain*. 18(1):99-107.

- [33] Katz, N.P., Paillard, F.C., & Edwards, R.R. (2015). Review of the performance of quantitative sensory testing methods to detect hyperalgesia in chronic pain patients on long-term opioids. *Anesthesiology*. 122(3):677-85.
- [34] Wasserman, R.A., Hassett, A.L., Harte, S.E., Goesling, J., Malinoff, H.L., Berland, D.W., et al. (2015). Pressure Pain Sensitivity in Patients With Suspected Opioid-Induced Hyperalgesia. *Reg Anesth Pain Med*. 40(6):687-93.
- [35] Sardá, J. Jr., Nicholas, M.K., Pimenta, C.A., & Asghari, A. (2008). Psychometric properties of the DASS-Depression scale among a Brazilian population with chronic pain. *Journal of psychosomatic research*. 64(1):25-31.
- [36] Lamers, L.M., McDonnell, J., Stalmeier, P.F., Krabbe, P.F., & Busschbach, J.J. (2006). The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. *Health Econ*. 15(10):1121-32.
- [37] Vartiainen, P., Mäntyselkä, P., Heiskanen, T., Hagelberg, N., Mustola, S., Forssell, H., et al. (2017). Validation of EQ-5D and 15D in the assessment of health-related quality of life in chronic pain. *Pain*. 158(8):1577-85.
- [38] Zoorob, R., Kowalchuk, A., & Mejia de Grubb, M. (2018). Buprenorphine Therapy for Opioid Use Disorder. *American family physician*. 97(5):313-20.
- [39] Ling, W., Charuvastra, C., Collins, J.F., Batki, S., Brown, L.S., Jr., Kintaudi, P., et al. (1998). Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. *Addiction*. 93(4):475-86.
- [40] Magnelli, F., Biondi, L., Calabria, R., Fiore, A., Peluso, E., Vonella, D., et al. (2010). Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study. *Clinical drug investigation*. 30 Suppl 1:21-6.
- [41] Farrar, J.T., Young, J.P., Jr., LaMoreaux, L., Werth, J.L., & Poole, M.R. (2001). Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. *Pain*. 94(2):149-58.
- [42] Semenkovich, K., Chockalingam, R., Scherrer, J.F., Panagopoulos, V.N., Lustman, P.J., Ray, J.M., et al. (2014). Prescription Opioid Analgesics Increase Risk of Major Depression: New Evidence, Plausible Neurobiological Mechanisms and Management to Achieve Depression Prophylaxis. *Mo Med*. 111(2):148-54.
- [43] Li, W., Sun, H., Chen, H., Yang, X., Xiao, L., Liu, R., et al. (2016). Major Depressive Disorder and Kappa Opioid Receptor Antagonists. *Transl Perioper Pain Med*. 1(2):4-16.
- [44] Mitchell, S.G., Gryczynski, J., Schwartz, R.P., Myers, C.P., O'Grady, K.E., Olsen, Y.K., et al. (2015). Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use. *J Psychoactive Drugs*. 47(2):149-57.
- [45] Yoshizawa, K., Kobayashi, H., Fujie, M., Ogawa, Y., Yajima, T., & Kawai, K. (2016). Estimation of minimal clinically important change of the Japanese version of EQ-5D in patients with chronic noncancer pain: a retrospective research using real-world data. *Health Qual Life Outcomes*. 14:35.
- [46] Davis, M.P., Pasternak, G., & Behm, B. (2018). Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option. *Drugs*. 78(12):1211-28.
- [47] Ellerbroek, H., van den Heuvel, S.A.S., Dahan, A., Timmerman, H., Kramers, C., & Schellekens, A.F.A. (2022). Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial. *Addiction science & clinical practice*. 17(1):47.

- [48] Veldman, S.E., Vroon, L.C., Melis, E.J., van den Heuvel, S.A.S., Schellekens, A.F.A., & Kramers, C. (2021). Opioiden afbouwen in de eerstelijnszorg. *Nederlands Tijdschrift van Geneeskunde*. 38.
- [49] Tripp, C.C., Rak, E., Burker, E. (2017). A Review of Effective Treatments for Patients With Co-Occurring Chronic Pain and Opioid Addiction. VISTAS Online.
- [50] Barbari, V., Storari, L., Ciuro, A., & Testa, M. (2020). Effectiveness of communicative and educative strategies in chronic low back pain patients: A systematic review. *Patient education and counseling*. 103(5):908-29.
- [51] Mittinty, M.M., Vanlint, S., Stocks, N., Mittinty, M.N., & Moseley, G.L. (2018). Exploring effect of pain education on chronic pain patients' expectation of recovery and pain intensity. *Scandinavian journal of pain*. 18(2):211-9.